Ocugen, Inc. (OCGN)

Market Cap	414.34M
Revenue (ttm)	7.05M
Net Income (ttm)	-58.50M
Shares Out	257.35M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	15.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,846,098
Open	1.590
Previous Close	1.625
Day's Range	1.580 - 1.750
52-Week Range	0.345 - 2.105
Beta	3.80
Analysts	Strong Buy
Price Target	4.67 (+190.06%)
Earnings Date	Aug 19, 2024

About OCGN

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy un...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Shankar Musunuri M.B.A., Ph.D.
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: OCGN

Financial Performance

In 2023, Ocugen's revenue was $6.04 million, an increase of 142.60% compared to the previous year's $2.49 million. Losses were -$63.08 million, -27.33% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for OCGN stock is "Strong Buy." The 12-month stock price forecast is $4.67, which is an increase of 190.06% from the latest price.

Price Target

$4.67

(190.06% upside)

Analyst Consensus: Strong Buy